Abstract
New therapeutic strategies are targeting correction of the basic defect in cystic fibrosis (CF) disease. In fact, completion of the first successful clinical drug trials now signals the start of a new era in CF therapy. Many promising drug candidates are emerging into the clinical drug pipeline. However, their translation from the bench to the bed side is challenged by the lack of accurate and reliable biomarker assays that allow testing for their clinical efficiency and safety in early clinical trials.
It is surprising that despite the availability of modern equipment and technologies relatively little effort has been directed towards innovative approaches to exploit our pathophysiological understanding of CF disease for the design of novel assays that allow in vivo assessment of CFTR dysfunction as the measurable correlate of the basic defect of CF disease. This lack of adequate outcome measure is now gaining increased attention, and first studies are being initiated to screen larger CF patient cohorts for biological markers that can be used as a potential measure of drug response. This paper reviews currently available in vivo tests, highlighting new methods and their potential use as early in vivo markers for therapeutic investigations. Finally, key criteria of the validation process that needs to be addressed before new biomarker assays can be introduced into clinical trials are discussed.
Keywords: Cystic fibrosis, CFTR function, biomarkers, therapy, mutant proteins, lung infections, absorptive epithelia, CFTR antibodies, respiratory airway epithelium, perturbations
Current Pharmaceutical Design
Title: Early In Vivo Testing to Assess New Therapeutic Interventions in CF Patients
Volume: 18 Issue: 5
Author(s): Tanja Gonska
Affiliation:
Keywords: Cystic fibrosis, CFTR function, biomarkers, therapy, mutant proteins, lung infections, absorptive epithelia, CFTR antibodies, respiratory airway epithelium, perturbations
Abstract: New therapeutic strategies are targeting correction of the basic defect in cystic fibrosis (CF) disease. In fact, completion of the first successful clinical drug trials now signals the start of a new era in CF therapy. Many promising drug candidates are emerging into the clinical drug pipeline. However, their translation from the bench to the bed side is challenged by the lack of accurate and reliable biomarker assays that allow testing for their clinical efficiency and safety in early clinical trials.
It is surprising that despite the availability of modern equipment and technologies relatively little effort has been directed towards innovative approaches to exploit our pathophysiological understanding of CF disease for the design of novel assays that allow in vivo assessment of CFTR dysfunction as the measurable correlate of the basic defect of CF disease. This lack of adequate outcome measure is now gaining increased attention, and first studies are being initiated to screen larger CF patient cohorts for biological markers that can be used as a potential measure of drug response. This paper reviews currently available in vivo tests, highlighting new methods and their potential use as early in vivo markers for therapeutic investigations. Finally, key criteria of the validation process that needs to be addressed before new biomarker assays can be introduced into clinical trials are discussed.
Export Options
About this article
Cite this article as:
Gonska Tanja, Early In Vivo Testing to Assess New Therapeutic Interventions in CF Patients, Current Pharmaceutical Design 2012; 18 (5) . https://dx.doi.org/10.2174/138161212799315948
DOI https://dx.doi.org/10.2174/138161212799315948 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Opportunities for Pregnane X Receptor (PXR) Targeting in Drug Development. Lessons from Enantio- and Species-Specific PXR Ligands Identified from A Discovery Library of Amino Acid Analogues
Mini-Reviews in Medicinal Chemistry The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Insulin Resistance in the HIV-Infected Population: The Potential Role of Mitochondrial Dysfunction
Current Drug Targets - Infectious Disorders Plant Natural Products in Anti-Diabetic Drug Discovery
Current Organic Chemistry Mechanisms for Progenitor Cell-Mediated Repair for Ischemic Heart Injury
Current Stem Cell Research & Therapy Cartilage Tissue Regeneration: The Roles of Cells, Stimulating Factors and Scaffolds
Current Stem Cell Research & Therapy An Overview of Naturally Occurring Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets An Introduction to the Structural Organization of Parasitic Protozoa
Current Pharmaceutical Design Regulation of Apoptosis and Activity of the Osteoclast
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti Diabetic Effect of Cherries in Alloxan Induced Diabetic Rats
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Plant Natural Products as a Potential Source for Antibacterial Agents: Recent Trends
Anti-Infective Agents in Medicinal Chemistry Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery The GABAergic System and the Gastrointestinal Physiopathology
Current Pharmaceutical Design Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Boundaries and Overlap between Hypochondriasis and Other Disorders: Differential Diagnosis and Patterns of Co-occurrence
Current Psychiatry Reviews Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Overcoming Drug Resistance and Treating Advanced Prostate Cancer
Current Drug Targets Use and Results of Antidepressant Treatment: Patients' Perception
Current Drug Therapy